List of Excipients in Branded Drug FIRAZYR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	FIRAZYR	icatibant acetate	54092-702	ACETIC ACID
Takeda Pharmaceuticals America Inc	FIRAZYR	icatibant acetate	54092-702	SODIUM CHLORIDE
Takeda Pharmaceuticals America Inc	FIRAZYR	icatibant acetate	54092-702	SODIUM HYDROXIDE

FIRAZYR Excipient Strategy and Commercial Opportunities for Icatibant Injection

Last updated: September 14, 2026

Firazyr is a preservative-free, ready-to-use subcutaneous injection containing icatibant acetate. Its commercial profile is driven less by excipient innovation than by usability, stability, device integration, manufacturing efficiency, and differentiated access for hereditary angioedema patients. The core formulation is difficult to improve materially without creating regulatory comparability risk, but meaningful opportunities exist in autoinjectors, smaller or more robust packaging systems, room-temperature logistics, and lower-cost generic supply.

What is Firazyr and how is it formulated?

Firazyr is the U.S. brand name for icatibant injection, a synthetic bradykinin B2-receptor antagonist used for acute attacks of hereditary angioedema in adults. The product is supplied as a sterile solution in a single-dose, prefilled syringe containing 30 mg of icatibant in 3 mL of solution. The approved route is subcutaneous administration. [1]

Formulation attribute	Firazyr profile
Active ingredient	Icatibant acetate
Strength	30 mg/3 mL
Concentration	10 mg/mL
Dosage form	Sterile injectable solution
Route	Subcutaneous
Container	Single-dose prefilled syringe
Preservative	None
pH	Approximately 5.0 to 5.5
Indication	Acute hereditary angioedema attacks in adults
Administration	Patient or caregiver self-injection after training

The labeled inactive ingredients are sodium chloride, citric acid monohydrate, sodium hydroxide, and water for injection. Sodium hydroxide adjusts pH, while sodium chloride supports tonicity. Citric acid provides buffering capacity. [1]

This is a relatively narrow excipient system. It avoids preservatives and complex stabilizer packages, which supports subcutaneous tolerability and self-administration. The formulation also reduces the number of potential composition-of-matter differences available to a generic developer.

What excipients are used in Firazyr?

The Firazyr excipient strategy is based on a simple aqueous peptide formulation:

Excipient	Primary formulation function	Commercial implication
Sodium chloride	Tonicity adjustment	Supports injection tolerability and osmolality control
Citric acid monohydrate	Buffer component and pH control	Helps maintain peptide stability within the target pH range
Sodium hydroxide	pH adjustment	Enables final pH correction during manufacture
Water for injection	Vehicle	Standard parenteral-grade solvent

The product does not use antimicrobial preservatives, surfactants, sugars, polyols, or amino-acid stabilizers in the labeled formulation. That creates both advantages and constraints.

The advantages are a short inactive-ingredient profile, low excipient burden, and a formulation that is easier to explain to patients and prescribers. The constraints include limited room to improve aggregation control, oxidation protection, interfacial stability, or freeze-thaw robustness through conventional excipient substitution.

For a generic product, the most defensible strategy is usually to match the reference formulation as closely as possible rather than pursue a novel excipient package. A materially different buffer, surfactant, or stabilizer may increase the burden for pharmaceutical equivalence, impurity characterization, subcutaneous tolerability, and clinical bridging.

What formulation risks matter for icatibant injection?

Icatibant is a synthetic peptide. The primary formulation risks are peptide aggregation, chemical degradation, adsorption to container surfaces, particulate formation, and changes caused by temperature excursions.

Important development variables include:

1. pH control across the product shelf life.
2. Control of subvisible and visible particulates.
3. Compatibility with syringe components and needle systems.
4. Stability under refrigerated and room-temperature conditions.
5. Protection from excessive agitation and repeated temperature cycling.
6. Extractables and leachables from the prefilled syringe and elastomeric components.
7. Container closure integrity.
8. Syringe glide force and injection force during self-administration.

A formulation that is chemically equivalent but difficult to inject can fail commercially. HAE patients may need to self-administer during painful or rapidly progressing attacks. Device performance, handling time, needle protection, and clarity of instructions are therefore part of the practical product value.

What excipient opportunities exist for Firazyr generics?

The strongest opportunity is not a radically new excipient. It is an excipient and container-closure package that preserves the reference product’s quality while reducing manufacturing cost or improving robustness.

Buffer optimization

A generic developer could evaluate citrate concentration and pH tolerance, but the commercial benefit is likely modest. The key objective is to maintain icatibant stability without increasing injection-site irritation. A narrow pH window may be preferable to a broader buffer system if it reduces degradation or improves comparability.

Surfactant screening

A low concentration of a peptide-compatible surfactant could reduce surface-induced aggregation or adsorption. This route carries risk because the reference product does not list a surfactant. Any addition would require justification under the applicable regulatory pathway and could introduce new concerns involving local tolerability, peroxide impurities, and container interactions.

Alternative stabilizers

Sugars, polyols, amino acids, or other peptide stabilizers may improve thermal or freeze-thaw stability. The commercial case is strongest if the change enables a meaningful supply-chain benefit, such as reduced cold-chain dependence or improved stability under excursion conditions. A stabilizer that only improves laboratory stress data without changing labeled storage or distribution requirements is unlikely to create significant value.

Low-binding container systems

Siliconized glass, polymer syringes, and alternative surface treatments can affect adsorption, aggregation, extractables, and injection force. A low-binding syringe may provide more practical value than a new liquid excipient because it can improve product consistency without changing the formulation composition.

Preservative-free multi-dose concepts

A multi-dose presentation would require a major redesign. The current single-dose, preservative-free format is aligned with self-administration and infection-control expectations. A multi-dose product would need robust antimicrobial protection or a validated device system. The regulatory and commercial burden would be high, and the use case is less obvious for an emergency rescue medicine.

What formulations and delivery systems could create commercial differentiation?

The principal formulation opportunity is to combine the existing aqueous solution with a more convenient delivery system.

Opportunity	Potential benefit	Main barrier
Autoinjector	Faster, simpler self-administration	Device development, human factors, combination-product requirements
Concealed-needle system	Reduced needle anxiety and handling errors	Higher device cost and validation burden
Smaller-footprint packaging	Better portability for patients	Dose volume remains 3 mL unless concentration changes
Polymer prefilled syringe	Lower breakage risk and design flexibility	Extractables, leachables, adsorption, and regulatory comparability
Higher-concentration formulation	Smaller injection volume	Peptide solubility, tolerability, stability, and device compatibility
Dual-pack emergency kit	Improved readiness for repeat dosing	Packaging, reimbursement, and inventory economics
Temperature-excursion-resistant product	Reduced distribution losses	Requires robust stability data and may not change labeled storage

A higher-concentration product could be commercially attractive because a 3 mL subcutaneous injection is relatively large for self-administration. However, increasing concentration can affect viscosity, injection force, local tolerability, peptide aggregation, and syringeability. The development program would need to demonstrate that the smaller volume does not compromise administration or safety.

An autoinjector is likely to offer more near-term differentiation than a new excipient system. It could reduce preparation steps and improve use during acute attacks. The commercial value would depend on payer coverage, device reliability, training requirements, and whether the product obtains a distinct regulatory or reimbursement position.

When did Firazyr lose regulatory exclusivity?

Firazyr received U.S. approval in August 2011. Its five-year new chemical entity exclusivity period therefore expired in 2016. [2] The product was approved before the current wave of oral and long-acting HAE therapies expanded the market.

Regulatory exclusivity and patent protection are separate. Expiration of NCE exclusivity permits certain abbreviated applications, but market entry also depends on listed patents, Paragraph IV certifications, litigation, settlement terms, manufacturing readiness, and FDA approval timing.

Milestone	Date or status
FDA approval of Firazyr	August 2011
Five-year NCE exclusivity	Expired in 2016
Product type	Synthetic peptide injection
Likely generic pathway	ANDA if pharmaceutical equivalence and bioequivalence requirements are met
Device risk	Higher if the applicant uses a materially different delivery system
Biosimilar pathway	Not applicable to icatibant

Icatibant is not a biologic for purposes of the U.S. biosimilar pathway. A competing icatibant product would generally be treated as a generic drug product rather than a biosimilar.

What is the Orange Book and Paragraph IV status of Firazyr?

The FDA Orange Book identifies approved drug products and certain patent and exclusivity information submitted by applicants. [3] For Firazyr, the relevant competitive questions are:

• Which patents, if any, remain listed for the reference product?
• What expiration dates and pediatric extensions apply?
• Has an applicant submitted a Paragraph IV certification?
• Has the reference sponsor filed a patent-infringement action?
• Does a 30-month stay affect approval timing?
• Does a settlement restrict launch timing or manufacturing activity?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If the patent holder files suit within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments. [4]

For investment and licensing analysis, the Orange Book should be reviewed together with FDA approval letters, federal court dockets, patent-family records, and any publicly disclosed settlement. A listed patent can delay approval, but it does not establish that a patent will withstand validity or infringement challenges.

How strong is the Firazyr patent estate?

The patent estate is likely weaker than that of a newer biologic or long-acting HAE therapy because the original approval dates to 2011 and the product uses a relatively simple aqueous formulation. The principal remaining barriers, where applicable, would be:

1. Formulation patents covering pH, excipient ratios, or stability characteristics.
2. Device patents covering the prefilled syringe or autoinjector.
3. Method-of-use patents covering acute HAE treatment, dosing, or repeat administration.
4. Manufacturing patents covering peptide synthesis, purification, or impurity control.
5. Regulatory exclusivity and litigation timing.

Composition-of-matter protection for icatibant is unlikely to be the principal commercial barrier at this stage. Formulation and device claims can still affect generic design, but their strength depends on claim scope, written-description support, prosecution history, prior art, and whether the proposed product practices the claimed limitations.

A generic developer may reduce risk by using a different syringe platform, altering noncritical process parameters, avoiding claimed excipient ranges, or developing a non-infringing device configuration. Such changes must remain compatible with pharmaceutical equivalence and product-quality requirements.

What manufacturing and IP barriers affect icatibant competition?

Manufacturing icatibant at commercial scale requires reliable peptide synthesis, purification, control of deletion sequences and related impurities, sterile filtration or aseptic processing, and validated filling into a prefilled syringe.

Key barriers include:

Barrier	Effect on market entry
Peptide impurity profile	Can increase analytical and process-validation burden
Aseptic filling	Requires specialized facilities and high-quality controls
Prefilled syringe supply	Creates dependence on device and component suppliers
Low-volume commercial market	May limit manufacturing scale economies
Cold-chain or controlled-temperature logistics	Increases inventory and distribution cost
Injection-device validation	Extends development timeline
Patient-use testing	Required for complex delivery systems
Payer access	Can limit uptake despite FDA approval

The most attractive contract-manufacturing opportunity is an integrated service covering peptide production, sterile fill-finish, prefilled syringe assembly, packaging, and stability testing. A supplier that can offer a qualified icatibant platform may reduce development time for multiple generic or regional applicants.

How does Firazyr compare with competing HAE products?

Firazyr competes in acute and preventive HAE treatment, but its most direct competitors are other on-demand products.

Product	Active ingredient	Role in HAE treatment	Formulation or commercial distinction
Firazyr	Icatibant	On-demand acute treatment	Ready-to-use subcutaneous peptide injection
Berinert	C1 esterase inhibitor	On-demand treatment and prevention in some markets	Plasma-derived protein requiring reconstitution
Ruconest	Recombinant C1 esterase inhibitor	On-demand treatment	Recombinant protein requiring reconstitution
Kalbitor	Ecallantide	On-demand treatment	Subcutaneous biologic administered by healthcare professionals
Takhzyro	Lanadelumab	Long-term prophylaxis	Long-acting monoclonal antibody
Orladeyo	Berotralstat	Oral prophylaxis	Daily oral therapy
Newer oral on-demand agents	Small-molecule therapies	Acute treatment	Potential convenience advantage over injections

Firazyr’s strongest product attributes are its ready-to-use format, subcutaneous route, and established self-administration profile. Its weaknesses include injection burden, a relatively large 3 mL dose, and competition from oral or longer-acting products.

What commercial opportunities exist for Firazyr excipients and drug delivery?

The most credible opportunities rank as follows:

1. Generic icatibant with a reference-matched excipient system

This is the lowest technical risk. The value proposition is cost, supply reliability, payer contracting, and regional availability rather than formulation novelty.

2. Autoinjector-enabled icatibant

An autoinjector could improve convenience and support premium positioning if the device reduces administration errors. The product would require human-factors validation and careful assessment of injection force for a 3 mL dose.

3. Higher-concentration icatibant

A smaller injection volume could address one of the product’s clearest usability limitations. The technical risk is substantial because concentration can affect stability, viscosity, aggregation, and local tolerability.

4. Polymer syringe or low-binding presentation

A modern container system could improve break resistance, portability, and supply-chain resilience. The development program would need to address extractables, leachables, adsorption, and compatibility with the existing solution.

5. Regional licensing and supply partnerships

Icatibant products may have value in markets where access to branded Firazyr is limited or where HAE diagnosis is increasing. Licensing a ready-to-use injectable platform to regional pharmaceutical companies may require less investment than developing a new molecule.

What is the revenue and market-entry exposure?

The commercial opportunity is concentrated in HAE patients who require rescue treatment and in health systems that reimburse self-administered emergency medicines. The market is relatively specialized, which limits total volume but can support high per-patient revenue.

Revenue exposure depends on:

• Number of diagnosed HAE patients.
• Use of on-demand versus prophylactic treatment.
• Frequency of attacks.
• Payer restrictions and prior authorization.
• Availability of competing oral therapies.
• Generic price erosion.
• Ability to secure specialty-pharmacy distribution.
• Patient preference for self-injection.
• Regional diagnosis and treatment rates.

A generic entrant could face rapid price pressure but still obtain attractive margins if it controls peptide synthesis and fill-finish costs. A differentiated device product may preserve higher pricing but will face greater development and reimbursement risk.

Key Takeaways

• Firazyr contains icatibant acetate in a preservative-free aqueous solution with sodium chloride, citric acid monohydrate, sodium hydroxide, and water for injection.
• Its five-year U.S. NCE exclusivity expired in 2016 following the 2011 FDA approval.
• The most practical generic strategy is close formulation matching rather than aggressive excipient redesign.
• The strongest product opportunity is an improved delivery system, particularly an autoinjector or smaller-volume presentation.
• A higher-concentration formulation could improve usability but carries meaningful stability, tolerability, and device risk.
• Icatibant competition is governed by generic-drug rules, not biosimilar rules.
• Formulation, device, manufacturing, and process patents may matter more than original molecule protection at this stage.
• Commercial success depends on specialty-pharmacy access, payer positioning, patient self-administration, and manufacturing scale.
• A contract-manufacturing platform combining peptide synthesis, sterile fill-finish, and prefilled-syringe assembly has licensing potential.

FAQs

Can Firazyr use preservatives in a reformulated product?

A reformulated product could theoretically use a preservative, but the current single-dose presentation is preservative-free. Adding a preservative would create new tolerability, regulatory, and comparability requirements without an obvious commercial benefit.

Is a 3 mL icatibant injection commercially vulnerable?

Yes. The 3 mL subcutaneous volume is a usability limitation and creates an opening for a higher-concentration formulation or device-assisted delivery system, provided stability and injection tolerability remain acceptable.

Can a generic icatibant product use different excipients?

Potentially, but a materially different excipient system can increase regulatory and clinical risk. A reference-matched formulation is generally the lower-risk path for an ANDA applicant.

Does Firazyr qualify for biosimilar competition?

No. Icatibant is a synthetic peptide drug, not a biological product subject to the U.S. biosimilar approval pathway. Competitors would generally pursue an abbreviated generic-drug pathway.

Which Firazyr opportunity has the best risk-adjusted profile?

A reference-matched generic with efficient peptide manufacturing and a reliable prefilled-syringe supply chain has the lowest technical risk. An autoinjector provides greater differentiation, while a higher-concentration formulation offers the largest usability upside but also the highest development risk.

References

1. U.S. Food and Drug Administration. (2023). Firazyr (icatibant acetate) injection: Prescribing information.
2. U.S. Food and Drug Administration. (2011). FDA approves Firazyr to treat hereditary angioedema attacks.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Amendments and abbreviated new drug applications.